title: New therapeutic targets in systemic lupus.
abstract: Glucocorticoids, aspirin, antimalarials and conventional immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets. In fact, belimumab, a human monoclonal antibody to BLyS inhibitor has become, in recent months, the first drug approved for the treatment of SLE since 1957, underscoring difficulties of all kinds, including economic and organizational ones inherent to clinical trials on this disease. Many other molecules are in various stages of development and soon will have concrete results. In this review, we examined the mechanism of action and most relevant clinical data for these molecules.
authors.affiliation: Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: Walter A
authors.initials: WA
authors.lastname: Sifuentes Giraldo
authors.forename: María J
authors.initials: MJ
authors.lastname: García Villanueva
authors.forename: Alina L
authors.initials: AL
authors.lastname: Boteanu
authors.forename: Ana
authors.initials: A
authors.lastname: Lois Iglesias
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Zea Mendoza
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000276:immunology; D015551:Autoimmunity; D002986:Clinical Trials as Topic; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007249:Inflammation; D007372:Interferons / Q000037:antagonists & inhibitors; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D008212:Lymphocyte Depletion; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D035703:Therapies, Investigational; D051193:Toll-Like Receptors / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D051056:Complement Inactivating Agents; D015507:Drugs, Investigational; D047428:Protein Kinase Inhibitors; D011993:Recombinant Fusion Proteins; D051193:Toll-Like Receptors; D007372:Interferons